Clinical Trial Update: Effect of Inflammasome Inhibitor on hsCRP in Patients After PCI [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating an inflammasome inhibitor's effect on hsCRP levels after PCI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Percutaneous Coronary Intervention Complications

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: NLRP3, hsCRP | Phase 4 | Status: COMPLETED